PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
Background. PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2020/3286139 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547135596265472 |
|---|---|
| author | Chiao-En Wu Ching-Fu Chang Liao Kou-Sheng Ju Chiang Shih-Wei Lee Yu-Chi Chiu |
| author_facet | Chiao-En Wu Ching-Fu Chang Liao Kou-Sheng Ju Chiang Shih-Wei Lee Yu-Chi Chiu |
| author_sort | Chiao-En Wu |
| collection | DOAJ |
| description | Background. PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and to find possible predictors of high PD-L1 expression. Materials and Methods. Data of 144 patients with histologically confirmed NSCLC and available PD-L1 measurements treated at the Taoyuan General Hospital from 2018 to 2019 were retrospectively reviewed in the study. Patients’ characteristics, including age, sex, clinical stage (T, N, and M) of NSCLC (AJCC, 8th edition), and EGFR/ALK alterations, were analyzed for association with PD-L1 expression. Results. Measurements of PD-L1 expression levels with Dako22C3 and Dako28-8 were comparable while SP142 showed lower levels of PD-L1 expression. The overall agreement between Dako22C3 and Dako28-8 was 82.2% and 91.6% for both 1% and 50% TPS cut-offs, respectively. The above findings were confirmed by Cohen’s kappa. In addition, we found that PD-L1 expression was significantly associated with advanced N stage but not with T and M stages. Conclusion. Dako22C3 and Dako28-8 showed comparable results in assessing PD-L1 levels. Future prospective studies are needed to validate these findings. N stage may be a good predictor for PD-L1 expression. |
| format | Article |
| id | doaj-art-28ba5343ed1047a58a1ba37da04a57df |
| institution | Kabale University |
| issn | 2210-7177 2210-7185 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Analytical Cellular Pathology |
| spelling | doaj-art-28ba5343ed1047a58a1ba37da04a57df2025-02-03T06:45:50ZengWileyAnalytical Cellular Pathology2210-71772210-71852020-01-01202010.1155/2020/32861393286139PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLCChiao-En Wu0Ching-Fu Chang1Liao Kou-Sheng2Ju Chiang3Shih-Wei Lee4Yu-Chi Chiu5Division of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, TaiwanDivision of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, TaiwanDepartment of Pathology, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, TaiwanDepartment of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, TaiwanDepartment of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, TaiwanDepartment of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, TaiwanBackground. PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and to find possible predictors of high PD-L1 expression. Materials and Methods. Data of 144 patients with histologically confirmed NSCLC and available PD-L1 measurements treated at the Taoyuan General Hospital from 2018 to 2019 were retrospectively reviewed in the study. Patients’ characteristics, including age, sex, clinical stage (T, N, and M) of NSCLC (AJCC, 8th edition), and EGFR/ALK alterations, were analyzed for association with PD-L1 expression. Results. Measurements of PD-L1 expression levels with Dako22C3 and Dako28-8 were comparable while SP142 showed lower levels of PD-L1 expression. The overall agreement between Dako22C3 and Dako28-8 was 82.2% and 91.6% for both 1% and 50% TPS cut-offs, respectively. The above findings were confirmed by Cohen’s kappa. In addition, we found that PD-L1 expression was significantly associated with advanced N stage but not with T and M stages. Conclusion. Dako22C3 and Dako28-8 showed comparable results in assessing PD-L1 levels. Future prospective studies are needed to validate these findings. N stage may be a good predictor for PD-L1 expression.http://dx.doi.org/10.1155/2020/3286139 |
| spellingShingle | Chiao-En Wu Ching-Fu Chang Liao Kou-Sheng Ju Chiang Shih-Wei Lee Yu-Chi Chiu PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC Analytical Cellular Pathology |
| title | PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC |
| title_full | PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC |
| title_fullStr | PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC |
| title_full_unstemmed | PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC |
| title_short | PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC |
| title_sort | pd l1 immunohistochemistry comparability and their correlation with clinical characteristics in nsclc |
| url | http://dx.doi.org/10.1155/2020/3286139 |
| work_keys_str_mv | AT chiaoenwu pdl1immunohistochemistrycomparabilityandtheircorrelationwithclinicalcharacteristicsinnsclc AT chingfuchang pdl1immunohistochemistrycomparabilityandtheircorrelationwithclinicalcharacteristicsinnsclc AT liaokousheng pdl1immunohistochemistrycomparabilityandtheircorrelationwithclinicalcharacteristicsinnsclc AT juchiang pdl1immunohistochemistrycomparabilityandtheircorrelationwithclinicalcharacteristicsinnsclc AT shihweilee pdl1immunohistochemistrycomparabilityandtheircorrelationwithclinicalcharacteristicsinnsclc AT yuchichiu pdl1immunohistochemistrycomparabilityandtheircorrelationwithclinicalcharacteristicsinnsclc |